Tuesday, March 31, 2020

Biocon#39;s insulin manufacturing facility in Malaysia gets EIR with VAI classification From USFDA

Biocon#39;s insulin manufacturing facility in Malaysia gets EIR with VAI classification From USFDA In a regulatory filing the company said, Biocon Sdn Bhd, a subsidiary of Biocon Ltd has received the EIR from the USFDA for the Pre-Approval Inspection (PAI) of its insulin manufacturing facility in Malaysia, for Insulin Glargine.

from Moneycontrol Business News https://ift.tt/3azKKTG
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Tariffs a temporary storm, structural reforms key for India: Arvind Sanger

Arvind Sanger of Geosphere Capital Management suggests a trade deal with the U.S. would benefit India by reducing market uncertainty and pro...